Rodman & Renshaw analyst Elmer Piros downgraded Athira Pharma to Neutral from Buy with a 75c price target. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on ATHA: Athira Pharma downgraded to Market Perform from Outperform at JMP Securities Athira Pharma downgraded to Neutral from Buy at BTIG Closing Bell Movers: GitLab up 14%, Zscaler down 14 after earnings Athira Pharma Discusses Clinical Trial and Financial Position Athira Pharma trading resumes Disclaimer & DisclosureReport an Issue
